Mavacamten
- CAS No.
- 1642288-47-8
- Chemical Name:
- Mavacamten
- Synonyms
- YMK-461;MYK-461;Mavacampten;MYK-461 (SAR-439152);Mawakatan;2,4(1H,3H)-Pyrimidinedione, 3-(1-methylethyl)-6-[[(1S)-1-phenylethyl]amino]-;SAR439152;SAR-439152;SAR 439152;Mavacamten
- CBNumber:
- CB23170382
- Molecular Formula:
- C15H19N3O2
- Molecular Weight:
- 273.33
- MDL Number:
- MFCD31746877
- MOL File:
- 1642288-47-8.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Density | 1.19±0.1 g/cm3(Predicted) |
|---|---|
| storage temp. | Storage temp. -20°C |
| solubility | insoluble in H2O; ≥11.32 mg/mL in EtOH with ultrasonic; ≥13.65 mg/mL in DMSO |
| form | solid |
| pka | 8.83±0.40(Predicted) |
| color | White to off-white |
| InChI | InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1 |
| InChIKey | RLCLASQCAPXVLM-NSHDSACASA-N |
| SMILES | C1(=O)NC(N[C@H](C2=CC=CC=C2)C)=CC(=O)N1C(C)C |
| FDA UNII | QX45B99R3J |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |    GHS07,GHS08,GHS09 |
|---|---|
| Signal word | Danger |
| Hazard statements | H302-H410-H372 |
| Precautionary statements | P264-P270-P273-P301+P312-P330-P391-P501 |
Mavacamten price More Price(61)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 19216 | Mavacamten ≥98% | 1642288-47-8 | 1mg | $69 | 2026-04-30 | Buy |
| Cayman Chemical | 19216 | Mavacamten ≥98% | 1642288-47-8 | 5mg | $167 | 2026-04-30 | Buy |
| Cayman Chemical | 19216 | Mavacamten ≥98% | 1642288-47-8 | 10mg | $297 | 2026-04-30 | Buy |
| Biosynth | SQC28847 | Mavacamten | 1642288-47-8 | 1g | $150 | 2026-06-05 | Buy |
| Biosynth | SQC28847 | Mavacamten | 1642288-47-8 | 5g | $154.7 | 2026-06-05 | Buy |
Mavacamten Chemical Properties, Uses, Production
Description
Mavacamten（MYK-461）is a first-in-class allosteric inhibitor of cardiac myosin that promises to provide clinicians with targeted therapy for these patients. It is a mechanistically novel small molecule that acts on the sarcolemma to specifically inhibit contractility and has been proposed as a treatment for HCM.
Uses
MYK-461 is a drug used to treat obstructive hypertrophic cardiomyopathy as a cardiac myosin inhibitor. Mavacamten is used to treat adults with symptomatic obstructive hypertrophic cardiomyopathy. It is used to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Application
Mavacamten (trade name Camzyos) is a small molecule cardiac myosin modulator indicated for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). oHCM is a monogenic cardiovascular disease caused by mutations in sarcomeric proteins, specifically myosin, that may affect up to 1 in 200 people.
Mechanism of action
Mavacamten is thought to work by reducing cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation that results in hypercontractility, left ventricular hypertrophy and reduced compliance. In clinical and preclinical studies, it has consistently reduced biomarkers of cardiac wall stress, lessened excessive cardiac contractility, and increased diastolic compliance.
Side effects
Common side effects of Mavacamten include: Dizziness, fainting, Incidence not known, Chest pain or tightness, decreased urine output, dilated neck veins, irregular breathing, irregular heartbeat, swelling of the face, fingers, feet, or lower legs, trouble breathing, unusual tiredness or weakness and weight gain.
Synthesis
Using isopropylamine (8.1) as the starting material, urea 8.2 can be obtained by treatment with trimethylsilyl isocyanate in a yield of 58% (Figure 2.3). Cyclization with dimethyl malonate can give the barbituric acid derivative 8.3 in a yield of 50%. The introduction of the chiral amine side chain is carried out in two steps. First, chlorination is carried out using pure phosphorus oxychloride (POCl3) and triethylbenzylammonium chloride (TEBAC) to obtain chloride 8.4 in a yield of 40%, and then it is treated with (S)-α-methylbenzylamine (8.5) to obtain white solid Mavacamten (8) in a yield of 69%.
Drug interactions
Mavacamten has a variable terminal t1/2 that depends on CYP2C19 metabolic status. Mavacamten's terminal half-life is 6-9 days in CYP2C19 normal metabolizers (NMs), which is prolonged in CYP2C19 poor metabolizers (PMs) to 23 days.
Mavacamten Preparation Products And Raw materials
Raw materials
Preparation Products
Mavacamten Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Cangzhou Kangrui Medical Technology Co., LTD | 18632776803 | cangzhoukangrui@126.com;355803330@qq.com | China | 678 | 58 |
| Shanghai Tube Pharmaceutical Co., Ltd. | 021-54338626 18017892860 | sales@tubepharm.com | China | 2709 | 58 |
| Changzhou Yongfeng Biomedicine Co. Ltd. | 15006117673 | 2973592490@qq.com | China | 270 | 58 |
| Chengdu Dorher Pharmaceutical CO.,Ltd | 028-64259743 19983537320 | wangmin@focuspharm.com | China | 498 | 58 |
| Shandong Jinhu Chemical Co., Ltd. | 18653796880 | sdjhhx@163.com | China | 34 | 58 |
| Suzhou Sino Rare Chemical Co., Ltd. | 512-62857507 | sales@sinorarechem.com | China | 1864 | 58 |
| ABBIOCHEM | 021-18964309092 18964309092 | 2769493375@qq.com | China | 430 | 58 |
| Cangzhou Enke Pharma-tech Co., Ltd. | 0317-5296180 15533709196 | enkepharma@126.com | China | 2495 | 55 |
| Shanghai jerryxing Biomedical Technology Co., Ltd | 17521512546 17721492509 | 460170712@qq.com | China | 4996 | 58 |
| Chembest Research Laboratories Limited | 021-20908456 | sales@BioChemBest.com | China | 5996 | 61 |
Related articles
- Mavacamten:Pharmacology,Mechanism and Adverse Effects
- Mavacamten is a small-molecule allosteric and reversible inhibitor of cardiac myosin ATPase. Herein its relevant information ....
- Dec 11,2025
View Latest Price from Mavacamten manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-09-17 | Mavacamten
1642288-47-8
|
$1.00 | 1g | 99.82% | 1000g | Jinan Million Pharmaceutical Co., Ltd | |
 |
2026-09-17 | Mavacamten
1642288-47-8
|
1KG | EP/USP | 1 ton | Hangzhou Hyper Chemicals Limited | ||
 |
2026-09-17 | Mavacamten
1642288-47-8
|
1g | More Than 99% | 100kg/Month | BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. |
-
- Mavacamten
1642288-47-8
- $1.00
- 99.82%
- Jinan Million Pharmaceutical Co., Ltd
-
- Mavacamten
1642288-47-8
- EP/USP
- Hangzhou Hyper Chemicals Limited
-
- Mavacamten
1642288-47-8
- $0.00
- More Than 99%
- BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
